drugset / Trial / NCT07249892
A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases
Phase 1/2
Not yet recruiting
195 enrolled
Chengdu Syncor Pharmaceutical Co., Ltd.
Beijing Quarkxia Technology Co., Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases
Timeline
- Start
- 2025-11-19
- Primary completion
- 2027-07-30
- Completion
- 2027-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BPR-6023021 | Other / unclassified | — | — |